Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders
By
Xianfu Sheng
Qijia Zheng
Jingjing Xiang
Nanxi Dong
Yuechao Zhao
Huijin Hu
Lili Qian
Wenbin Liu
Jianping Shen
Baodong Ye
Yu Zhang
April 21, 2026
Clinical Scorecard: Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders
At a Glance
Category Detail
Condition Plasma Cell Disorders Key Mechanisms Thrombopoietin receptor agonist enhancing megakaryocytic recovery Target Population Adults with multiple myeloma or AL amyloidosis undergoing ASCT Care Setting Single-center retrospective cohort study
Key Highlights
Romiplostim N01 accelerates platelet engraftment (median 11 vs. 13 days; P = 0.008) Complete platelet recovery by day +30 was higher in Romiplostim N01 cohort (100% vs. 66.7%; P = 0.027) Total hospitalization cost significantly lower with Romiplostim N01 (77,609 ± 21,624 CNY vs. 106,188 ± 14,910 CNY; P < 0.001) Comparable safety profiles and treatment responses between groups Non-cryopreserved PBSCs reduce toxicity and costs associated with ASCT Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of multiple myeloma or AL amyloidosis Assess eligibility for ASCT based on institutional criteria Management
Utilize Romiplostim N01 with non-cryopreserved PBSCs to enhance platelet recovery Consider granulocyte colony-stimulating factor (G-CSF) for stem-cell mobilization Monitoring & Follow-up
Monitor platelet engraftment and recovery timelines Assess transfusion requirements and hospitalization duration Risks
Monitor for potential adverse effects of Romiplostim N01 Evaluate risks associated with platelet transfusions and alloimmunization Patient & Prescribing Data
Adults ≥18 years with confirmed multiple myeloma or AL amyloidosis
Early administration of Romiplostim N01 post-ASCT improves outcomes and reduces costs
Clinical Best Practices
Integrate Romiplostim N01 with non-cryopreserved PBSCs for optimal thrombopoietic support Adhere to institutional protocols for ASCT eligibility and patient management References
